BioNotebook: NephroGenex, Dicerna, Argos IPO terms; Pluristem data; NanoViricides offering
This article was originally published in Scrip
Executive Summary
Another round of US stock market hopefuls set preliminary price ranges for initial public offerings intended to subject the now-private biotechnology companies to public investor scrutiny: NephroGenex, Dicerna Pharmaceuticals and Argos Therapeutics.